CNBC Utilities Page Drugs

More

  • Microsoft partners with pot software

    CNBC's Eamon Javers reports Microsoft is adding pot industry software provider "KIND Financial" to its government solutions package.

  • Jane: The dispensary's best mechanical friend

    CNBC's Kate Rogers reports from Denver about a kiosk start-up taking on the marijuana industry.

  • Meet Jane, the cannabis industry’s kiosk solution

    In a niche where cash is king, one marijuana kiosk start-up wants to improve the sales buzz for retailers and customers. CNBC's Kate Rogers reports.

  • Diver down

    Despite the drop in the use of painkillers by hurt workers, such medications remain commonly prescribed to them in many states.

  • June 8- A U.S. advisory panel on Wednesday recommended approval of Pfizer Inc's long-acting opioid painkiller Troxyca ER, saying it dulls pain and its design could deter abuse by addicts in search of a quick high. The panel, however, had reservations about the drug's ability to curb all forms of abuse, voting against a claim that it deters oral abuse while endorsing...

  • A preliminary FDA review issued on Friday concluded Vantrela ER had properties deterring abuse through snorting or injecting, but the abuse-resistant benefit was less clear when the product was swallowed. The FDA is not obliged to follow the advice of its expert panels but typically does so. The FDA's approval for drugs it considers effective for treating...

  • June 7- A U.S. advisory panel recommended approving Teva Pharmaceuticals Industries Ltd's long-acting opioid painkiller, Vantrela ER, saying data showed it reduces pain and has some abuse-resistant properties. The FDA is not obliged to follow the advice of its expert panels but typically does so. A preliminary FDA review issued on Friday concluded Vantrela...

  • June 7- A U.S. advisory panel recommended approving Teva Pharmaceuticals Industries Ltd's long-acting opioid painkiller, Vantrela ER, saying data showed it reduces pain and has some abuse-resistant properties. The FDA is not obliged to follow the advice of its expert panels but typically does so. A preliminary FDA review issued on Friday concluded Vantrela...

  • June 7- A U.S. advisory panel recommended approval of Teva Pharmaceuticals Ltd's long-acting opioid painkiller, saying data showed it reduces pain and has some abuse-resistant properties. The drug is designed for use every 12 hours for the management of pain severe enough to require around-the-clock treatment in patients who have not derived enough...

  • Ariad confident on cancer drug data

    Ariad Pharmaceuticals President and CEO Paris Panayiotopoulos, discusses patient response to cancer treatment Brigatinib.

  • Roche's fight against cancer

    CNBC's Meg Tirrell speaks with Daniel O'Day, Roche Holdings CEO of Pharmaceuticals Division, at the ASCO Conference about the company's cancer drug developments and the state of the pharmaceuticals industry.

  • June 6- A long-acting opioid painkiller being developed by Pfizer Inc has the potential to deter abuse but can be manipulated, a preliminary review by the U.S. Food and Drug Administration showed. FDA reviewers said in a report published on Monday that oxycodone could be selectively extracted from intact pellets by a number of straightforward techniques and...

  • June 6- An experimental, long-acting opioid painkiller from Pfizer Inc showed potential to deter abuse but can be manipulated, according to a preliminary review by the U.S. Food and Drug Administration. The review was published on the agency's website on Monday and comes ahead of a June 8 meeting of outside experts, who will discuss the drug and recommend whether...

  • June 3- An experimental, long-acting painkiller made by Teva Pharmaceutical Industries Ltd does not have abuse-resistant properties when taken orally, according to a preliminary review by the U.S. Food and Drug Administration. The FDA is not obliged to follow the advice of its advisory panels but typically does so. The abuse of opioids- a class of drugs that...

  • An FDA spokesman on Friday afternoon said the agency staff was still working on the preliminary review of the treatment. FDA staff members on Friday asked the panel to deliberate on whether the painkiller should be approved for the proposed indication, and if it should carry a label that shows the product is less subject to oral, nasal and intravenous abuse.

  • The case for more antibiotics

    A drug resistant bacteria is putting health officials on high alert, in which some are looking at the need for new antibiotics. Ezekiel Emanuel, Center for American Progress, discusses the dangers of over-prescription, and urges creation of new antibiotics.

  • Misinformation on Theranos: Kovacevich

    Richard Kovacevich, former Wells Fargo CEO, thinks the news around Theranos is not unusual for a startup. Forbes has revised the net worth of Theranos founder Elizabeth Holmes.

  • US Death rate rises for the first time in a decade

    Research shows more Americans are now dying from drug overdoses, suicide, and Alzheimer's disease.

  • Black Market

    Ecstasy is becoming popular again in the European Union, with online sales and targeted marketing helping to drive the revival.

  • Probuphine, a buprenorphine implant for long-term maintenance treatment of opioid addiction.

    Probupine contains a medication that in oral form has become a popular tool for eliminating opioid withdrawal symptoms.